Shots:
- Lyell has acquired global rights to LYL273 (excl. mainland China, Hong Kong, Macau & Taiwan) for the treatment of metastatic colorectal cancer & other GCC-expressing cancers from ICT
- As per the deal, ICT will receive $40M upfront, 1.9M Lyell shares, ~$30M in clinical, ~$115M in late-stage regulatory, & ~$675M in sales milestones, plus ~1.85M additional shares tied to clinical & regulatory milestones, with tiered royalties from mid-single digits up to 10% in the US & low to mid-single digits in other licensed states
- In P-I trial, LYL273 showed ORR of 50% (6/12) & DCR of 83% across both doses; at Dose Level 2, ORR reached 67% (4/6) with one pathological CR, one 100% PR, two confirmed PRs, DCR of 83%, & mPFS of 7.8mos. Updated data is expected in H1’26
Ref: GlobeNewswire | Image: Lyell Immunopharma & Innovative Cellular Therapeutics | Press Release
Related News:- Transition Bio Inks ~$500M Pact with Voyager Therapeutics to Develop Small Molecules for Neurodegenerative Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
